Toxicology Letters 1989-10-01

Mutagenicity testing of doxylamine succinate, an antinauseant drug.

L Müller, A Korte, S Madle

Index: Toxicol. Lett. 49(1) , 79-86, (1989)

Full Text: HTML

Abstract

Doxylamine succinate (DA), a compound which was formerly used as an antinauseant during pregnancy, showed no substantial mutagenicity in mouse embryos following transplacental exposure. A small dose-dependent induction of chromosomal aberrations was found in mouse embryos on day 11 of gestation. No induction of sister chromatid exchanges (SCE) was found in embryos on day 11 of gestation. A micronucleus test with fetal blood on day 17 of gestation was negative. Additionally, DA was negative in Chinese hamster bone marrow in vivo (micronuclei) and in human lymphocyte cultures in vitro (SCE).

Related Compounds

  • DOXYLAMINE S...

Related Articles:

Use of In Vitro Morphogenesis of Mouse Embryoid Bodies to Assess Developmental Toxicity of Therapeutic Drugs Contraindicated in Pregnancy.

2016-01-01

[Toxicol. Sci. 149 , 15-30, (2016)]

[Nontraumatic rhabdomyolysis due to oral poisoning by doxylamine succinate].

1997-03-08

[Med. Clin. (Barc.) 108(9) , 356, (1997)]

Safety assessment of OTC drugs: doxylamine succinate.

1995-01-01

[Arch. Toxicol. Suppl. 17 , 326-40, (1995)]

Dose-response trend tests for tumorigenesis, adjusted for body weight.

1999-06-01

[Toxicol. Sci. 49(2) , 318-23, (1999)]

Desorption chemical ionization and fast atom bombardment mass spectrometric studies of the glucuronide metabolites of doxylamine.

1986-11-01

[Biomed. Environ. Mass Spectrom. 13(11) , 627-32, (1986)]

More Articles...